Psychopharm Cmte. Crafts Statement To Avoid Public Misunderstanding
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee crafted a statement on the need for long-term efficacy data for psychiatric drugs in order to avoid public misperception of the outcome of its Oct. 25 meeting
You may also be interested in...
Antidepressant Long-Term Efficacy Pre-Approval Would Delay New Therapies
FDA's Psychopharmacologic Drugs Advisory Committee on Oct. 25 agreed with industry's key argument that the proposed requirement to complete long-term efficacy studies at the time of approval for major depressive disorder drugs would delay the entry of new therapies to market
Antidepressant Long-Term Efficacy Pre-Approval Would Delay New Therapies
FDA's Psychopharmacologic Drugs Advisory Committee on Oct. 25 agreed with industry's key argument that the proposed requirement to complete long-term efficacy studies at the time of approval for major depressive disorder drugs would delay the entry of new therapies to market
Antidepressant Long-Term Efficacy Pre-Approval Will Be Voted On By Cmte.
FDA will ask whether it is reasonable to require both acute and long-term efficacy data in applications for antidepressants and other chronic psychiatric drugs at its Psychopharmacologic Drugs Advisory Committee meeting on Oct. 25